Abata Therapeutics

Abata Therapeutics

  • Founded: 2021
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: MS
  • Drug types: IMM, NEU, END, MUS
  • Lead product: ABA-101
  • Product link: https://abatatx.com/our-programs/
  • Funding: $95M A Jun 2021



job board

Short description:

Treg Cell Therapies

Drug notes:

Undisclosed programs RD diabetes (1), RD inclusion body myositis

Long description:

Abata Therapeutics is understanding the biology of T cells to create therapies for autoimmune diseases. Regulatory T cells (Tregs) are a critical component of the immune system that act to suppress the immune response preventing autoimmunity. Abata is using this knowledge to engineer Tregs as targeted therapies that stop immune-mediated destruction of normal cells and restore homeostasis. Treg engineering involves expression of a T cell receptor that recognizes a tissue-restricted antigen, to selectively target the therapy to the site of disease for a robust response. In addition, engineered Tregs are optimized for durability allowing the effects of a single dose to last years. Abata has initial programs for multiple sclerosis and Type 1 diabetes.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com